Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis
Vor Bio completed enrollment in UPSTREAM MG, its global Phase 3 registrational trial of telitacicept in generalized myasthenia gravis, with topline results from the 24-week primary endpoint still on track for the first half of 2027. The company also plans to initiate UPSTREAM oMG, a second global Phase 3 registrational trial in ocular myasthenia gravis, with first patient dosing anticipated in the first half of 2027, extending the telitacicept franchise across the MG spectrum.
Key figures
- Drug Name
- telitacicept
- Phase Of Trial
- Phase 3
- Primary endpoint
- change from baseline in MG-ADL score at Week 24
- Topline data timing
- first half of 2027
- Open label extension
- 48 weeks
- Placebo controlled period
- 24 weeks
- China approved indications
- ["SLE","RA","gMG","IgAN","SjD"]
- Omg trial first patient dosing
- first half of 2027
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.